US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with Swiss pharmaceutical giant Novartis AG (NYSE: NVS) to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer treatment.
Details of the Agreement
Ratio will apply its radioligand therapy discovery and development expertise, along with its SSTR2-targeted radiopharmaceutical technology platform, to collaborate with Novartis on the preclinical development and research of the SSTR2 targeted candidate product. Novartis will take the lead on subsequent development, manufacturing, and commercialization activities. Under the terms of the deal, Ratio is set to receive up to USD 745 million in upfront and potential milestone payments, as well as tiered royalty payments.
Ratio Therapeutics’ R&D Platforms
Ratio Therapeutics boasts proprietary R&D platforms, Trillium and Macropa, which facilitate the development of fit-for-purpose radiopharmaceuticals for both therapy and imaging. The company is also progressing in the development of its first FAP-targeted radiotherapeutic, with plans to initiate clinical trials next year.-Fineline Info & Tech
Leave a Reply